LYEL 250117 0.50P (LYEL250117P500) Stock Options, News & Quotes

US OptionsDetailed Quotes

LYEL250117P500

Watchlist

0.05
0.000.00%

15min DelayClose Dec 24 13:00 ET

0.05High0.05Low

Intraday

5D
Daily

News

Morgan Stanley Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $4
Moomoo NewsDec 24 08:32 ET · Ratings
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)
TipRanksDec 24 08:30 ET · Ratings
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Zacks Dec 13 08:40 ET
Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024
BenzingaDec 10 01:58 ET
Lyell Immunopharma Announces Promising Initial Clinical Data for IMPT-314 in Treatment of CAR T-Naïve Patients With Large B-Cell Lymphoma
Quiver QuantitativeDec 9 21:10 ET
Express News | Lyell Immunopharma Inc - Impt-314 Receives Fast Track Designation From FDA
ReutersDec 9 21:01 ET

Comments

Teddy123

Dec 10 03:06

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

$Lyell Immunopharma (LYEL.US)$
Lyell's IMPT-314 Cancer Therapy Shows Stunning 94% Response Rate in Lymphoma Trial

Wins333

Nov 20 14:11

$Lyell Immunopharma (LYEL.US)$ what a day

Teddy123

Nov 8 05:40

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

$Lyell Immunopharma (LYEL.US)$
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphoma
Presenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024...

Teddy123

Nov 7 07:15

When will u start moving

$Lyell Immunopharma (LYEL.US)$

Teddy123

Nov 5 08:39

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

$Lyell Immunopharma (LYEL.US)$
05/11/2024 - 22:30
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, ...